Results 221 to 230 of about 52,424 (257)
Some of the next articles are maybe not open access.
Novel developments in the treatment of acute bacterial skin and skin structure infections
Expert Opinion on Pharmacotherapy, 2019Introduction: Acute bacterial skin and skin structure infection (ABSSSI) represents a major burden for healthcare systems. The increased prevalence of Methicillin-resistant Staphylococcus aureus, combined with the limited availability of microbiologic data when treating ABSSSI, has led to a need for more convenient, less toxic anti-MRSA agents.
Danya Roshdy +2 more
exaly +3 more sources
Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections
Current Opinion in Infectious Diseases, 2020 Purpose of review To summarize the available efficacy and safety data of novel agents for treating acute bacterial skin and skin-structure infections (ABSSSI), focusing on those active against methicillin-resistant Staphylococcus aureus (MRSA).
Bassetti, Matteo +3 more
openaire +4 more sources
Expert Review of Anti-infective Therapy, 2023 Acute bacterial skin and skin structure infections (ABSSSIs) are a subtype of skin and soft tissue infections (SSTI), usually sustained by Gram-positive bacteria, whose incidence is high among children. ABSSSIs are responsible for a considerable number of hospitalizations.
Lorenzo Volpicelli +2 more
openaire +3 more sources
The safety of treatment options for acute bacterial skin and skin structure infections
Expert Opinion on Drug Safety, 2019 Acute bacterial skin and skin-structure infections (ABSSSI) may develop in both in-patients and out-patients, possibly with a severe clinical presentation. Since most phase 3 randomized clinical trials have shown non-inferiority in efficacy across different agents, considerations regarding their different safety profiles inevitably play a crucial role ...
Bassetti M. +3 more
openaire +5 more sources
Current and emerging drugs for acute bacterial skin and skin structure infections: an update
Expert Opinion on Emerging Drugs, 2014Antibiotic resistance, the emergence of multidrug-resistant bacteria and the exponential rise of methicillin-resistant Staphylococcus aureus (MRSA) acute bacterial skin and skin structure infections (ABSSSI) pose a great threat to the public health.
Ramya, Kollipara +5 more
exaly +3 more sources
Oritavancin: A Review in Acute Bacterial Skin and Skin Structure Infections
Drugs, 2015Oritavancin (Orbactiv(®)) is a new generation lipoglycopeptide approved for use in adult patients with acute bacterial skin and skin structure infections (ABSSSI). It is administered as a single 1200 mg intravenous infusion over 3 h. In phase 3 trials in adult patients with ABSSSI, oritavancin was noninferior to vancomycin in terms of a composite ...
Yahiya Y, Syed, Lesley J, Scott
openaire +2 more sources
Tedizolid for treatment of acute bacterial skin and skin structure infections
Expert Review of Anti-infective Therapy, 2015Tedizolid is a newly approved drug of the oxazolidinone class. It has high in vitro activity against Gram-positive bacteria, including multidrug-resistant strains. Peak plasma concentration of tedizolid is obtained within 3 h of oral dosing (PO), with high bioavailability.
Ye, Hui, Lü, Xiaoju
openaire +2 more sources
Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections
The Nurse Practitioner, 2018Abstract: Acute bacterial skin and skin structure infections (ABSSSIs) are some of the most commonly encountered infections worldwide. Hospitalizations as a result of ABSSSIs are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, the two newest lipoglycopeptides, in the context of the other ...
Allison M, Bell +5 more
openaire +3 more sources
Managing acute bacterial skin and skin structure infections
The Nurse Practitioner, 2017Abstract: Acute bacterial skin and skin structure infections (ABSSSI) are some of the most commonly encountered infections worldwide. Hospitalizations as a result of ABSSSI are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, two new lipoglycopeptides, in the context of the other I.
Allison M, Bell +5 more
openaire +2 more sources
Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections
Expert Review of Clinical Pharmacology, 2014Skin infections have traditionally been classified by the US FDA as uncomplicated and complicated. In August 2010, the FDA released a new guidance document for the development of drugs to treat acute bacterial skin and skin structure infections (ABSSSI) and this was updated in 2013.
Eric, Beresford +5 more
openaire +2 more sources